Physician profile
Ying Chen
NPI 1689038531
$1,775.76
in general payments reported to CMS, 2019-2025
11 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $74.82 · 2021: $298 · 2022: $237 · 2023: $292 · 2024: $91.56 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.48 | 2022-2024 | |
| Allergan, INC. | $270.59 | 2019 | |
| Amgen INC. | $265.27 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $227.54 | 2019-2023 | Tepezza |
| Alcon Vision LLC | $218.88 | 2020-2021 | |
| Axogen | $149.03 | 2023 | Avance Nerve Graft |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.24 | 2021 | |
| Kedrion Biopharma, INC. | $115.43 | 2025 | Ryplazim |
| Astellas Pharma US INC | $46.74 | 2025 | Vyloy |
| Johnson & Johnson Surgical Vision, INC. | $31.56 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.